Skip to main content

Table 3 A, B and C Proteins identified as selectively altered in CAA type-1

From: Proteomics analysis identifies new markers associated with capillary cerebral amyloid angiopathy in Alzheimer’s disease

Gene Protein P-val C vs CAA P-val AD vs CAA FDR C vs CAA FDR AD vs CAA FC C vs CAA FC AD vs CAA # detections Control # detections AD # detections CAA
A. Significant CAA versus control and CAA versus Alzheimer's disease
 CLU Clusterin;Clusterin beta chain;Clusterin alpha chain 0.000 0.000 0.001 0.007 4.47 2.33 6 7 7
 APOE Apolipoprotein E 0.001 0.001 ns ns 4.97 2.11 6 7 7
 SUCLG2 Succinyl-CoA ligase [GDP-forming] subunit beta, mitochondrial 0.002 0.002 ns ns 2.17 0.61 5 7 7
 PPP2R4 Serine/threonine-protein phosphatase 2A activator 0.026 0.010 ns ns 2.18 0.80 6 7 7
 KTN1 Kinectin 0.015 0.021 ns ns 0.34 0.40 2 2 3
 ACTG1 Actin, cytoplasmic 2;Actin, cytoplasmic 2, N-terminally processed 0.000 0.035 ns ns 0.80 0.90 6 7 7
 TNR Tenascin-R 0.007 0.017 ns ns 0.82 0.82 6 7 7
 COL6A3 Collagen alpha-3(VI) chain 0.016 0.024 ns ns 7.79 4.95 3 5 7
 NFASC Neurofascin 0.028 0.040 ns ns 0.86 0.87 6 7 7
B. Significant CAA versus control or Alzheimer’s disease and ≤1 detection in other group
 APP Amyloid beta A4 protein;N-APP;Soluble APP-alpha;Soluble APP-beta; NA 0.000 NA ns NA 6.65 1 7 7
 UBLCP1 Ubiquitin-like domain-containing CTD phosphatase 1 NA 0.007 NA ns NA 1.96 1 2 4
 SRI Sorcin NA 0.011 NA ns NA 0.25 1 3 5
 NDP Norrin NA 0.020 NA ns NA 5.16 0 4 7
 PNP Purine nucleoside phosphorylase NA 0.030 NA ns NA 1.72 0 3 3
 C1orf123 UPF0587 protein C1orf123 NA 0.047 NA ns NA 0.71 0 6 6
 DHX15 Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 0.005 NA ns NA 0.44 NA 3 0 5
 SYNPO Synaptopodin 0.015 NA ns NA 0.44 NA 4 1 4
 TPM1 Tropomyosin alpha-1 chain 0.021 NA ns NA 0.37 NA 3 1 3
 CADPS2 Calcium-dependent secretion activator 2 0.042 NA ns NA 1.22 NA 2 1 3
 SERPINA3 Alpha-1-antichymotrypsin;Alpha-1-antichymotrypsin His-Pro-less 0.042 NA ns NA −0.86 NA 2 1 3
C. ≤1 detection in control and Alzheimer's disease and ≥4 in CAA OR ≤1 in CAA and ≥4 in Alzheimer’s disease and control
 HLA-DRA;HLA-DQA2 HLA class II histocompatibility antigen, DR alpha chain;HLA class II histocompatibility antigen, DQ alpha 2 chain NA NA NA NA NA NA 0 1 7
 HTRA1 Serine protease HTRA1 NA NA NA NA NA NA 0 1 7
 APCS Serum amyloid P-component;Serum amyloid P-component(1–203) NA NA NA NA NA NA 0 1 6
 COL6A2 Collagen alpha-2(VI) chain NA NA NA NA NA NA 0 1 5
 MOB2 MOB kinase activator 2 NA NA NA NA NA NA 1 1 5
 POTEI POTE ankyrin domain family member I NA NA NA NA NA NA 1 0 4
 KIAA1468 LisH domain and HEAT repeat-containing protein KIAA1468 NA NA NA NA NA NA 1 0 4
 TMF1 TATA element modulatory factor NA NA NA NA NA NA 0 1 4
 SGIP1 SH3-containing GRB2-like protein 3-interacting protein 1 NA NA NA NA NA NA 4 4 1
  1. Proteins were found using the three different selection methods as described in Fig. 2
  2. AD Alzheimer’s disease, CAA cerebral amyloid angiopathy, FDR false discovery rate, NA not applicable, NS not significant, FC fold change